×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang
Natco Q3 PAT may dip 24% YoY to Rs. 165 cr: Sharekhan
Natco Pharma Q3 PAT may dip 30.3% YoY to Rs. 151.7 cr: ICICI Direct
Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan
Natco Pharma Q2 PAT seen up 118.2% YoY to Rs. 185 cr: ICICI Direct
Natco Pharma Q4 PAT seen up 78.5% YoY to Rs. 315.3 cr: Edelweiss
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
Natco Pharma Q4 PAT may dip 26.8% to Rs 156.1 cr: ICICI Securities
Natco Pharma Q3 PAT seen up 6.1% to Rs 70.3 cr: ICICI Securities
Pharma biz to drive Jubilant Life's future growth: Surajit Pal
Natco Pharma Q1 PAT seen down by 24.1% at Rs 45.7 cr: Religare
Natco Pharma Q1 PAT seen down 34.1% to Rs 39.7 cr: Edelweiss
Pharma companies revenues to rise 12% in Q3: Anand Rathi
Patent win against Teva to boost revenues: Natco Pharma
See Rs 20-25cr in revenue/quarter from Lanzoprazol: Natco
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio